PHLDA1 and cancer: Finally, we have extrapolated our findings to other RTK-driven cancers, using cell-based, in vivo and bioinformatics approaches, to identify PHLDA1 as a mediator of resistance with direct relevance to a broad range of RTK-targeted therapies.